DARPA Archives
COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study
Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
Possible COVID-19 “decoy”
Oct. 15, 2020—It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
Antibodies eye Pacific Island “fever”
May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
New method tested to block chikungunya infection
Jun. 14, 2019—Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
VUMC-led team ‘sprints’ to develop Zika virus treatment
Apr. 11, 2019—In January scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus.
New way to stimulate learning?
Mar. 14, 2019—Vagus nerve stimulation could be beneficial for treating Alzheimer’s disease and other forms of cognitive impairment, Vanderbilt research findings suggest.
VUMC scientists ‘sprint’ to find anti-Zika antibodies
Jan. 24, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.
New imaging approach offers unprecedented views of staph infection
Mar. 15, 2018—A new integrated imaging approach makes it possible to probe the molecules involved in invasive infections and can be broadly applied to any health or disease state.
VUMC joins national effort to block global pandemics of potentially lethal viruses
Jan. 11, 2018—The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.
VU joins national effort to speed Ebola therapy testing
Apr. 8, 2015—Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.
Vanderbilt’s neurovascular chip project moves into new phase
Nov. 18, 2014—Vanderbilt researchers will play a key role in the second phase of the federal "tissue chip for drug screening" program.
